T1925 |
PLX647
|
873786-09-5
|
|
|
PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).
|
T78603 |
Sotuletinib dihydrochloride
|
2222138-40-9
|
98%
|
|
Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM. It pr...
|
T79472 |
CSF1R-IN-17
|
|
98%
|
|
CSF1R-IN-17 (compound 9) is a potent, selective antagonist of CSF1R, exhibiting an inhibition concentration half-maximum (IC50) of 0.2 nM. It is capable of inhib...
|
T79815 |
C-Fms-IN-14
|
1898210-99-5
|
98%
|
|
c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].
|
T80585 |
Anti-Mouse GM-CSF Antibody (MP1-22E9)
|
|
98%
|
|
Anti-Mouse GM-CSF Antibody is a rat-derived IgG2a isotype inhibitor that targets mouse granulocyte-macrophage colony-stimulating factor (GM-CSF).
|
T10648 |
C-Fms-IN-9
|
1628574-50-4
|
98%
|
|
c-Fms-IN-9 is a c-FMS inhibitor. It inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT (IC50s: <0.01 μM and 0.1-1 μM).
|
T69759 |
IACS-9439
|
2231259-57-5
|
98%
|
|
IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM. It is applicable in the research of advanced solid tumors [1]....
|
T12505 |
PLX5622 hemifumarate
|
|
98%
|
|
PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor with an IC 50 of 0.016 μM and Ki of 5.9 nM. PLX5622 hemifumarate all...
|
T10645 |
C-Fms-IN-6
|
1628574-81-1
|
98%
|
|
c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: > 1 μM).
|
T10649 |
C-Fms-IN-3
|
885704-21-2
|
99.92%
|
|
c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.
|
T2609 |
Masitinib
|
790299-79-5
|
99.91%
|
|
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 200...
|
T10643 |
C-Fms-IN-1
|
885703-64-0
|
99.88%
|
|
c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).
|
T5586 |
CFMS Receptor Inhibitor II
|
959860-85-6
|
99.86%
|
|
cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor
|
T61589 |
C-Fms-IN-13
|
885704-58-5
|
99.83%
|
|
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.
|
T79157 |
Pimicotinib
|
2253123-16-7
|
99.8%
|
|
Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.
|
T2624 |
OSI-930
|
728033-96-3
|
99.76%
|
|
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
|
T60087 |
CFMS Receptor Inhibitor IV
|
959626-45-0
|
99.73%
|
|
cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.
|
TQ0015 |
PRN1371
|
1802929-43-6
|
99.72%
|
|
PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).
|
T13194 |
CSF1R-IN-2
|
2271119-26-5
|
99.71%
|
|
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
|
T6930 |
Pazopanib Hydrochloride
|
635702-64-6
|
99.69%
|
|
Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM...
|